AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24662398
Drug: evolocumab 140
RxNorm normalized name: evolocumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: evolocumab 140 mg Q2 W
Trial: 24662398
Drug: evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: evolocumab 420 mg QM
Trial: 23381198
Drug: Methylprednisolone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (1000 mg intravenously during anesthesia induction)
Trial: 17130328
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no steroid administration)
Trial: 2958234
Drug: Silicone spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone spray
Trial: 12952498
Drug: Tetracycline 250
RxNorm normalized name: tetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 250 mg with centchroman 30 mg
Trial: 12952498
Drug: Tetracycline 250
RxNorm normalized name: tetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 250 mg, centchroman 30 mg, and lactic acid bacillus spores (60 million)
Trial: 10647760
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with nitrendipine (10-40 mg/d), possibly with captopril (12.5-50 mg/d) and/or hydrochlorothiazide (12.5-50 mg/d)
Trial: 24863570
Drug: targeted ultraviolet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: targeted ultraviolet B (tUVB) treatment
Trial: 16091074
Drug: Overall (Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall (Morphine vs Pethidine)
Trial: 9707384
Drug: Levomethadyl acetate
RxNorm normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levomethadyl acetate (LAAM) high-dose (100 mg) induction lasting 17 days
Trial: 9707384
Drug: Levomethadyl acetate
RxNorm normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levomethadyl acetate (LAAM) low-dose (25 mg) induction
Trial: 9707384
Drug: Levomethadyl acetate
RxNorm normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levomethadyl acetate (LAAM) medium-dose (50 mg) induction lasting 7 days
Trial: 7713467
Drug: Enzyme combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme combination preparation
Trial: 761334
Drug: Reorganized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reorganized treatment group
Trial: 16408442
Drug: Ordinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary treatment group
Trial: 23406077
Drug: 50/50 nitrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/50 nitrous oxide and oxygen at 9 L/min (N(2) O group)
Trial: 23406077
Drug: Medical air
RxNorm normalized name: Medical air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical air at 9 L/min (MA group)
Trial: 21224456
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (pelvic floor muscle training and bladder control strategies)
Trial: 21224456
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy plus biofeedback and pelvic floor electrical stimulation
Trial: 15520341
Drug: ATHENA program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATHENA program (8 weekly 45-minute sessions)
Trial: 9607373
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg mibefradil
Trial: 9607373
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg mibefradil
Trial: 9234827
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg mibefradil
Trial: 9234827
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg mibefradil
Trial: 1451721
Drug: Clomipramine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine treatment
Trial: 3596358
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of aspirin
Trial: 334185
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of aspirin
Trial: 28953493
Drug: Zinc lozenges
RxNorm normalized name: Zinc Lozenges
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc lozenges (40 mg) administered 30 minutes preoperatively
Trial: 23190837
Drug: Oral rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral rivaroxaban (10 mg) once daily for 10 days, starting 6 to 8 hours after surgery
Trial: 23190837
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo once daily for 10 days, starting 6 to 8 hours after surgery
Trial: 20160653
Drug: High-dose vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamins (2 g vitamin C and 800 IU vitamin E)
Trial: 20160653
Drug: Methionine loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine loading (100 mg/kg body weight)
Trial: 14622687
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg etoricoxib
Trial: 10742934
Drug: 9-month, manual-based,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-month, manual-based, psychoeducational family therapy
Trial: 10742934
Drug: Independent observers'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Independent observers' ratings of overall treatment difficulty
Trial: 9003103
Drug: Anticardiolipin antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticardiolipin antibodies (IgG or IgM)
Trial: 9003103
Drug: Anticardiolipin antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticardiolipin antibodies (IgA)
Trial: 1728527
Drug: 5-ASA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA (2 g/day)
Trial: 6093236
Drug: Low secretory
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low secretory IgA concentrations in IM patients, mean value 0.180 g/l
Trial: 2942457
Drug: 0.3% foscarnet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% foscarnet cream for men
Trial: 2942457
Drug: 1% foscarnet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% foscarnet cream for women
Trial: 2942457
Drug: foscarnet cream
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: foscarnet cream (both dosages)
Trial: 22275463
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality therapy
Trial: 16929448
Drug: Preoperative epoetin-alpha
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative epoetin-alpha treatment added to standard care
Trial: 11756667
Drug: scopolamine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine (0.4 mg)
Trial: 9789200
Drug: Melimmune-1 and
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melimmune-1 and Melimmune-2 administered with SAF-m adjuvant
Trial: 2703174
Drug: Intracavitary irradiation
RxNorm normalized name: carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracavitary irradiation using high dose-rate afterloading technique with 60Co sources
Trial: 2703174
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (hysterectomy and radiotherapy)
Trial: 342631
Drug: monovalent (A/New
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monovalent (A/New Jersey/76) vaccine, single dose
Trial: 342631
Drug: split-product vaccines,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: split-product vaccines, two-dose regimen
Trial: 342631
Drug: bivalent (A/New
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent (A/New Jersey/76-A/Victoria/75) vaccines, high doses of split-product
Trial: 342631
Drug: whole-virus vaccines
RxNorm normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: whole-virus vaccines
Trial: 30358156
Drug: L-arginine (17.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (17.1 mmol)
Trial: 23240499
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine subunit strain A/California/7/2009/(H1N1)v
Trial: 18418962
Drug: Oxymatrine plus
RxNorm normalized name: Oxymatrine
DrugBank: Oxymatrine (DB16276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymatrine plus Western routine therapy
Trial: 18418962
Drug: Western routine
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western routine therapy (Control)
Trial: 12844131
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral dexamethasone regimen (20 mg on day 1, 8 mg on days 2 to 5) plus ondansetron (32 mg IV on day 1)
Trial: 12844131
Drug: Modified dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified dexamethasone regimen (12 mg on day 1, 4 mg on days 2 to 5) plus ondansetron (32 mg IV on day 1)
Trial: 12844131
Drug: Methylprednisolone regimen
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone regimen (125 mg IV on day 1, 40 mg orally on days 2 to 3) with aprepitant (125 mg on day 1, 80 mg on days 2 to 3)
Trial: 10325897
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP), 500 micrograms twice daily
Trial: 10325897
Drug: Budesonide (BUD),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (BUD), 800 micrograms twice daily
Trial: 8612314
Drug: Ftorafur (FT)
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ftorafur (FT) 600 mg/day
Trial: 8612314
Drug: Ftorafur (FT)
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ftorafur (FT) 600 mg/day plus Tamoxifen (TAM) 20 mg/day
Trial: 1787937
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone 1%
Trial: 31429150
Drug: Fractional excretion
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional excretion of UA
Trial: 12366503
Drug: Fluid administration
RxNorm normalized name: Fluid Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid administration <1 litre
Trial: 12366503
Drug: Fluid administration
RxNorm normalized name: Fluid Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid administration ≥1 litre
Trial: 12366503
Drug: No fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No fluid administration (Control)
Trial: 11041318
Drug: Zolmitriptan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan (5 mg per os)
Trial: 2055827
Drug: High-carbohydrate diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-carbohydrate diet (10 g.kg body mass‐1.day‐1)
Trial: 2055827
Drug: Moderate-carbohydrate diet
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-carbohydrate diet (5 g.kg body mass‐1.day‐1)
Trial: 7081096
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day zinc supplementation
Trial: 7081096
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day zinc supplementation
Trial: 7081096
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day zinc supplementation
Trial: 7081096
Drug: 0 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/day zinc supplementation (placebo)
Trial: 1095310
Drug: Nystatin therapy
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nystatin therapy
Trial: 28631901
Drug: Perforated ultra‐lightweight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perforated ultra‐lightweight polypropylene implant (surface density 19 g/m2)
Trial: 28631901
Drug: Lightweight polypropylene
RxNorm normalized name: polypropylene (30000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lightweight polypropylene implant (surface density 42.7 g/m2)
Trial: 21205556
Drug: Zinc in
RxNorm normalized name: Zinc insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc in tablet form
Trial: 21205556
Drug: Zinc in
RxNorm normalized name: Zinc insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc in suspension form
Trial: 21205556
Drug: WHO recommended
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [WHO Recommended Hand Rub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO recommended treatment for diarrhoea
Trial: 17395055
Drug: Cardiac contractility
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac contractility modulation (CCM) therapy; delivered continuously for 30 minutes in patients and 2 hours in dogs
Trial: 16128874
Drug: Advice to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice to drink 1.5 l of water per day
Trial: 11870165
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m² IV every 21 days
Trial: 11870165
Drug: Cyclophosphamide 500
RxNorm normalized name: cyclophosphamide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 500 mg/m², Doxorubicin 50 mg/m², and Cisplatin 50 mg/m² (CAP) IV every 21 days
Trial: 10197659
Drug: Pump prime
RxNorm normalized name: DELTYL PRIME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pump prime only aprotinin (280 mg)
Trial: 3476058
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated aspirin 20 mg daily
Trial: 3476058
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated aspirin 40 mg daily
Trial: 3476058
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated aspirin 60 mg daily
Trial: 3476058
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated aspirin 60-80 mg daily
Trial: 3476058
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated aspirin greater than 100 mg daily
Trial: 3476058
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated aspirin 80 mg daily
Trial: 3476058
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated aspirin 100 mg daily
Trial: 22913409
Drug: Heat patch
RxNorm normalized name: CVS Body Heat Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat patch containing iron chip
Trial: 15859526
Drug: Sham short-wave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham short-wave diathermy treatment (control)
Trial: 11801587
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B 3 mg/kg/day
Trial: 11801587
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B 5 mg/kg/day
Trial: 11801587
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B lipid complex (ABLC) 5 mg/kg/day
Trial: 10401542
Drug: Eight week
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight week rehabilitation programme combining group and individual therapies
Trial: 8904255
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil (50 mu g in 10 ml normal saline)
Trial: 8904255
Drug: Control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (10 ml normal saline)
Trial: 8904255
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil (50 mu g in 50 ml bupivacaine 0.125% at a rate of 6-10 ml/h)
Trial: 1919423
Drug: Non-pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmacological treatment (NPT) programme
Trial: 31471246
Drug: Blonanserin 40
RxNorm normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Blonanserin 40 mg
Trial: 31471246
Drug: Blonanserin 80
RxNorm normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Blonanserin 80 mg
Trial: 30115212
Drug: Willingness to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willingness to prescribe antidepressants
Trial: 26273146
Drug: I-gel facilitated
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-gel facilitated endotracheal tube intubation (Group TI)
Trial: 22525775
Drug: Combined Treatment
RxNorm normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Treatment (AT/RT)
Trial: 19788364
Drug: Vaginal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estrogen therapy (creams, tablets, rings)
Trial: 17971946
Drug: BCG-PSN injection
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG-PSN injection plus inhaled glucocortisteriods
Trial: 17971946
Drug: Inhaled glucocortisteriods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocortisteriods only
Trial: 10548622
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 1.5% lignocaine (group A)
Trial: 10548622
Drug: No local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No local injection (group C)
Trial: 31607677
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/day plus rifaximin 1200 mg/day
Trial: 31607677
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day plus rifaximin 1200 mg/day
Trial: 25882778
Drug: Tetracycline 250
RxNorm normalized name: tetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 250 mg every 12h for 4 weeks
Trial: 19398277
Drug: Hydrocortisone (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (35 mg)
Trial: 15470487
Drug: AB killer
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AB killer cell immunoglobulin-like receptor (KIR) phenotype in leukemic patients
Trial: 15470487
Drug: AB killer
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AB killer cell immunoglobulin-like receptor (KIR) phenotype in healthy controls
Trial: 11467911
Drug: Scopolamine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (intravenous injection)
Trial: 11467911
Drug: Glycopyrrolate (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (intravenous injection)
Trial: 7976460
Drug: Treatment program
RxNorm normalized name: ZO Skin Health Acne Prevention Plus Treatment Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment program (details not specified)
Trial: 3371882
Drug: Intravenous hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hypertonic glucose (900 mOsmoles per liter) at 2 ml per min
Trial: 31863865
Drug: Tofacitinib ECS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib ECS tablets (11 mg and 22 mg)
Trial: 31863865
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg immediate-release formulation tablet
Trial: 30181096
Drug: Nemonoxacin 500
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 500 mg once daily for 7-10 days
Trial: 30181096
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg once daily for 7-10 days